Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Modern Diagnostic & Research Centre EBITDA Margin %?
Modern Diagnostic & Research CentreBOM:544673 15 EBITDA Margin % is 13.76% as of Mar. 2026, which is 22% below its 10-year median of 17.56. GuruFocus rates BOM:544673 with a GF Score™ of 15/100. The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Modern Diagnostic & Research Centre ranks better than 61.88% on this metric.
Modern Diagnostic & Research Centre (BOM:544673) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Modern Diagnostic & Research Centre EBITDA Margin % Related Terms
Modern Diagnostic & Research Centre EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Diagnostic & Research Centre EBITDA Margin % Chart
Modern Diagnostic & Research Centre Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
-1.23
18.73
24.27
16.38
Modern Diagnostic & Research Centre Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
0.00
0.00
0.00
13.76
BOM:544673 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Modern Diagnostic & Research Centre's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modern Diagnostic & Research Centre EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Modern Diagnostic & Research Centre's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Modern Diagnostic & Research Centre's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Diagnostic & Research Centre (BOM:544673) has a EBITDA Margin % of 13.76% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Modern Diagnostic & Research Centre and its competitors. This is 22% below median its historical median of 17.56. According to the industry distribution chart, Modern Diagnostic & Research Centre ranks #77 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 38.1%.
Is Modern Diagnostic & Research Centre's EBITDA Margin % too high?
Modern Diagnostic & Research Centre's current EBITDA Margin % of 13.76% is 22% below median its 10-year median of 17.56. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.69. Modern Diagnostic & Research Centre's value of 13.76% is 142% above this industry median. Based on the distribution chart, Modern Diagnostic & Research Centre ranks #77 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Modern Diagnostic & Research Centre has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Modern Diagnostic & Research Centre's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Modern Diagnostic & Research Centre ranks #77 out of 202 companies for EBITDA Margin %. This puts Modern Diagnostic & Research Centre in the upper half of its industry. The industry median EBITDA Margin % is 5.69. Modern Diagnostic & Research Centre's value of 13.76% is 142% above this benchmark. While the company's 10-year median is 17.56 vs. the industry median of 5.69, Modern Diagnostic & Research Centre has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.69, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modern Diagnostic & Research Centre's current EBITDA Margin % of 13.76% is 142% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Modern Diagnostic & Research Centre and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modern Diagnostic & Research Centre's current EBITDA Margin % is 13.76%, which is 22% below median its own 10-year median of 17.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Diagnostic & Research Centre stock overvalued right now?
Modern Diagnostic & Research Centre (BOM:544673) has a current EBITDA Margin % of 13.76%. The current EBITDA Margin % is 13.76%, which is 22% below median its 10-year median of 17.56 and 142% above the Medical Diagnostics & Research industry median of 5.69. Modern Diagnostic & Research Centre's overall GF Score™ is 15/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Modern Diagnostic & Research Centre (BOM:544673), the current EBITDA Margin % is 13.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modern Diagnostic & Research Centre Ltd is a services provider in diagnostic and related healthcare tests services in India. It offers a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through Its integrated, nationwide network, it offers a complete range of diagnostic facilities in radiology and pathology. The company provides healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
15GF Score
Get the complete analysis for BOM:544673
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544673 has been successfully added to your 
